Terms: = Lung cancer AND MYCL, LMYC, 4610, MYCL1, ENSG00000116990
172 results:
1. C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer.
Lang C; Megyesfalvi Z; Lantos A; Oberndorfer F; Hoda MA; Solta A; Ferencz B; Fillinger J; Solyom-Tisza A; Querner AS; Egger F; Boettiger K; Klikovits T; Timelthaler G; Renyi-Vamos F; Aigner C; Hoetzenecker K; Laszlo V; Schelch K; Dome B
World J Surg Oncol; 2024 Feb; 22(1):57. PubMed ID: 38369463
[TBL] [Abstract] [Full Text] [Related]
2. An in-silico analysis reveals further evidence of an aggressive subset of lung carcinoids sharing molecular features of high-grade neuroendocrine neoplasms.
Pelosi G; Melocchi V; Dama E; Hofman P; De Luca M; Albini A; Gemelli M; Ricotta R; Papotti M; La Rosa S; Uccella S; Harari S; Sonzogni A; Asiedu MK; Wigle DA; Bianchi F
Exp Mol Pathol; 2024 Feb; 135():104882. PubMed ID: 38237798
[TBL] [Abstract] [Full Text] [Related]
3. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Bauer TM; Moore KN; Rader JS; Simpkins F; Mita AC; Beck JT; Hart L; Chu Q; Oza A; Tinker AV; Imedio ER; Kumar S; Mugundu G; Jenkins S; Chmielecki J; Jones S; Spigel D; Fu S
Target Oncol; 2023 Jul; 18(4):517-530. PubMed ID: 37278879
[TBL] [Abstract] [Full Text] [Related]
4. MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer.
Alburquerque-Bejar JJ; Navajas-Chocarro P; Saigi M; Ferrero-Andres A; Morillas JM; Vilarrubi A; Gomez A; Mate JL; Munoz-Marmol AM; Romero OA; Blecua P; Davalos V; Esteller M; Pros E; Llabata P; Torres-Diz M; Esteve-Codina A; Sanchez-Cespedes M
Cell Rep Med; 2023 Apr; 4(4):101006. PubMed ID: 37044092
[TBL] [Abstract] [Full Text] [Related]
5. Clinical significance of MYC family protein expression in surgically resected high-grade neuroendocrine carcinoma of the lung.
Oshima Y; Haruki T; Matsui S; Makishima K; Sakabe T; Umekita Y; Nakamura H
Thorac Cancer; 2023 Mar; 14(8):758-765. PubMed ID: 36694106
[TBL] [Abstract] [Full Text] [Related]
6. [Susceptibility study on the germline rare variants of bromodomain and extraterminal domain protein family-encoding genes and patients with cancer living in some regions of China].
Huang Y; Li JH; Wang X; Zou Y; Huang WF; Liu C; Zhang H
Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(42):3374-3381. PubMed ID: 36372767
[No Abstract] [Full Text] [Related]
7. Molecular Subtypes of Extra-pulmonary Neuroendocrine Carcinomas Identified by the Expression of Neuroendocrine Lineage-Specific Transcription Factors.
Metovic J; La Salvia A; Rapa I; Napoli F; Birocco N; Pia Bizzi M; Garcia-Carbonero R; Ciuffreda L; Scagliotti G; Papotti M; Volante M
Endocr Pathol; 2022 Sep; 33(3):388-399. PubMed ID: 35608806
[TBL] [Abstract] [Full Text] [Related]
8. Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer.
Tsuboyama N; Wang R; Szczepanski AP; Chen H; Zhao Z; Shi L; Wang L
Oncogene; 2022 Apr; 41(15):2152-2162. PubMed ID: 35194152
[TBL] [Abstract] [Full Text] [Related]
9. How serious are we about protecting workers health? The case of diesel engine exhaust.
Vermeulen R; Portengen L
Occup Environ Med; 2022 Aug; 79(8):540-542. PubMed ID: 35149598
[TBL] [Abstract] [Full Text] [Related]
10. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.
Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H
J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680
[TBL] [Abstract] [Full Text] [Related]
11. cancer mortality in a population-based cohort of American Indians - The strong heart study.
Rhoades DA; Farley J; Schwartz SM; Malloy KM; Wang W; Best LG; Zhang Y; Ali T; Yeh F; Rhoades ER; Lee E; Howard BV
Cancer Epidemiol; 2021 Oct; 74():101978. PubMed ID: 34293639
[TBL] [Abstract] [Full Text] [Related]
12. mycl1 Amplification and Expression of L-Myc and c-Myc in Surgically Resected Small-Cell lung Carcinoma.
Qin J; Xie F; Li C; Han N; Lu H
Pathol Oncol Res; 2021; 27():1609775. PubMed ID: 34257619
[No Abstract] [Full Text] [Related]
13. Co-immunization with L-Myc enhances CD8
Chai D; Zhang Z; Jiang N; Ding J; Qiu D; Shi SY; Wang G; Fang L; Li H; Tian H; Yang J; Zhang Q; Zheng J
Cancer Sci; 2021 Sep; 112(9):3469-3483. PubMed ID: 34157192
[TBL] [Abstract] [Full Text] [Related]
14. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.
Ponce Aix S; Novello S; Garon EB; Nakagawa K; Nadal E; Moro-Sibilot D; Alonso Garcia M; Fabre E; Frimodt-Moller B; Zimmermann AH; Visseren-Grul CM; Reck M;
Cancer Treat Res Commun; 2021; 27():100378. PubMed ID: 33905962
[TBL] [Abstract] [Full Text] [Related]
15. Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer.
Patel AS; Yoo S; Kong R; Sato T; Sinha A; Karam S; Bao L; Fridrikh M; Emoto K; Nudelman G; Powell CA; Beasley MB; Zhu J; Watanabe H
Sci Adv; 2021 Jan; 7(5):. PubMed ID: 33514539
[TBL] [Abstract] [Full Text] [Related]
16.
Grunblatt E; Wu N; Zhang H; Liu X; Norton JP; Ohol Y; Leger P; Hiatt JB; Eastwood EC; Thomas R; Ibrahim AH; Jia D; Basom R; Eaton KD; Martins R; Houghton AM; MacPherson D
Genes Dev; 2020 Sep; 34(17-18):1210-1226. PubMed ID: 32820040
[TBL] [Abstract] [Full Text] [Related]
17. MAX Functions as a Tumor Suppressor and Rewires Metabolism in Small Cell lung cancer.
Augert A; Mathsyaraja H; Ibrahim AH; Freie B; Geuenich MJ; Cheng PF; Alibeckoff SP; Wu N; Hiatt JB; Basom R; Gazdar A; Sullivan LB; Eisenman RN; MacPherson D
Cancer Cell; 2020 Jul; 38(1):97-114.e7. PubMed ID: 32470392
[TBL] [Abstract] [Full Text] [Related]
18. MYC, mycl, and MYCN as therapeutic targets in lung cancer.
Massó-Vallés D; Beaulieu ME; Soucek L
Expert Opin Ther Targets; 2020 Feb; 24(2):101-114. PubMed ID: 32003251
[No Abstract] [Full Text] [Related]
19. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer.
Dammert MA; Brägelmann J; Olsen RR; Böhm S; Monhasery N; Whitney CP; Chalishazar MD; Tumbrink HL; Guthrie MR; Klein S; Ireland AS; Ryan J; Schmitt A; Marx A; Ozretić L; Castiglione R; Lorenz C; Jachimowicz RD; Wolf E; Thomas RK; Poirier JT; Büttner R; Sen T; Byers LA; Reinhardt HC; Letai A; Oliver TG; Sos ML
Nat Commun; 2019 Aug; 10(1):3485. PubMed ID: 31375684
[TBL] [Abstract] [Full Text] [Related]
20. Tumor Heterogeneity Underlies Differential Cisplatin Sensitivity in Mouse Models of Small-Cell lung cancer.
Böttger F; Semenova EA; Song JY; Ferone G; van der Vliet J; Cozijnsen M; Bhaskaran R; Bombardelli L; Piersma SR; Pham TV; Jimenez CR; Berns A
Cell Rep; 2019 Jun; 27(11):3345-3358.e4. PubMed ID: 31189116
[TBL] [Abstract] [Full Text] [Related]
[Next]
